Skip to main content

Table 1 Inflammation markers during the patient follow up

From: Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome

Date

Age

Leucocytes ×109/L

Neutrophils ×109/L

CRP mg/L

June 2015

2 y 10 mo

8.27

7.51

114.09

April 2016

3 y 8 mo

16.62

11.01

23.71

November 2016

4 y 3 mo

16.12

12.16

16.3

January 2017

4 y 5 mo

10.81

9.11

76.18

March 2017

4 y 7 mo

10.89

5.12

43.04

Start of Baricitinib in August 2017

 September 2017

5 y 0 mo

16.88

12.24

2.8

 October 2017

5 y 2 mo

8.73

3.5

0.13

 December 2017

5 y 4 mo

7.66

3.53

8.78

 February 2018

5 y 5 mo

7.89

4.47

17.13

 April 2018

5 y 7 mo

6.74

2.78

7.48

 February 2019

6 y 5 mo

7.5

5.79

18.63